RDIF and rostec to establish production of the drug in blood plasma for treatment COVID-19

Holding “Nazimiye” rostec Corporation and the Russian direct investment Fund have agreed to launch a joint project for the production of the drug in blood plasma for treatment COVID-19. According to the press service of Rostec, the company has its own technology for production of human immunoglobulin, is able to counteract the virus.

Made on the basis of blood plasma of patients recover from a drug containing antibodies to the SARS coronavirus CoV-2, will be called “Biogas”, at the moment he has successfully passed the first phase of clinical trials.

According to the Director of Rostec Sergey Chemezov, after the registration of drug manufacturing can be deployed in four sites in Perm, Nizhny Novgorod, Tomsk and Ufa.

Investments obtained in the framework of cooperation with the FUND, will be used to purchase equipment, clinical trials, preparation of documents for registration of the drug.

Leave a Reply

Your email address will not be published. Required fields are marked *

Releated

For the six months Kurgan “Synthesis” increased revenue by 42%

Revenue of JSC “Sintez” (part of the Allium Group) for 6 months of 2020 has increased by 42% year-on-year to 6,767 billion. Net profit reached 752.9 million roubles that on 23% more than in the same period last year. Export sales grew by 36% year-on-year, exceeding 1 billion rubles, told in the company. Secondary sales […]

Russia confirmed on 5 065 new cases COVID-19

In recent days in Russia identified 5 065 new cases of coronavirus in 83 regions. Died 114 people, fully recovered 6 568 patients. In Moscow confirmed 688 new cases of coronavirus. The average rate of increase of new cases for the first two weeks of August is 0.28%. This figure compares with the first two […]